MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 108.8 USD | +0.89% |
|
+5.23% | +9.45% |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 24 | Moderna to Collaborate With OpenAI to Launch New Generation of Medicines | MT |
Financials (USD)
| Sales 2024 * | 4.21B | Sales 2025 * | 4.83B | Capitalization | 41.31B |
|---|---|---|---|---|---|
| Net income 2024 * | -2.81B | Net income 2025 * | -2.08B | EV / Sales 2024 * | 8.69 x |
| Net cash position 2024 * | 4.73B | Net cash position 2025 * | 3.38B | EV / Sales 2025 * | 7.85 x |
| P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-20.3
x | Employees | 5,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.39% |
More Fundamentals
* Assessed data
More news
Latest transcript on Moderna, Inc.
More recommendations
More press releases
More news
| 1 day | +1.75% | ||
| 1 week | +4.88% | ||
| Current month | +2.15% | ||
| 1 month | +3.24% | ||
| 3 months | +6.80% | ||
| 6 months | +38.42% | ||
| Current year | +9.45% |
1 week
99.30
111.29
1 month
97.00115.89
Current year
84.06115.97
1 year
62.55142.79
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 51 | 11-02-28 |
James Mock
DFI | Director of Finance/CFO | 47 | 22-09-05 |
Stephen Hoge
PSD | President | 48 | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 65 | 18-05-31 |
| Director/Board Member | 74 | 20-06-30 | |
Francois Nader
BRD | Director/Board Member | 67 | 19-12-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.66% | 0 M€ | 0.00% | - | |
| 4.69% | 2 M€ | -.--% | ||
| 4.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 108.8 | +0.89% | 3,388,825 |
| 24-04-23 | 107.9 | +3.28% | 2,435,253 |
| 24-04-22 | 104.5 | +3.01% | 3,176,356 |
| 24-04-19 | 101.4 | -0.58% | 2,670,446 |
| 24-04-18 | 102 | -1.39% | 1,798,498 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
107.9
USD
Average target price
134.3
USD
Spread / Average Target
+24.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.45% | 41.31B | |
| +4.09% | 43.43B | |
| +47.81% | 41.69B | |
| -10.92% | 27.14B | |
| +9.32% | 25.28B | |
| -24.87% | 18.47B | |
| +29.70% | 12.59B | |
| +1.28% | 12.33B | |
| +7.78% | 11.03B | |
| -17.68% | 10.01B |
- Stock Market
- Equities
- MRNA Stock
